Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conventional efficacy of PRGF in atrophic vulvar lichen sclerosus
2021-006474-23Phase 3Active
- Sponsor
- BTI Biotechnology Institute
- Start
- Dec 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of PRGF-Endoret in Kraurosis vulvae (2 arms), sponsored by BTI Biotechnology Institute. Primary endpoint: Primary: Skindex-29 quality of life at 6 and 8 months. Started Dec 2021; status: active.
02
Drugs
PRGF-Endoret
03
Conditions
Kraurosis vulvae
Beyond the preview
Go deeper on 2021-006474-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006474-23.